Mitochondria and Mitochondrial Cascades in Alzheimer’s Disease
Open accessThe DOI matches its Crossref record; 153 of the 154 references it cites were found in a registry or an index.
Abstract
Decades of research indicate mitochondria from Alzheimer’s disease (AD) patients differ from those of non-AD individuals. Initial studies revealed structural differences, and subsequent studies showed functional deficits. Observations of structure and function changes prompted investigators to consider the consequences, significance, and causes of AD-related mitochondrial dysfunction. Currently, extensive research argues mitochondria may mediate, drive, or contribute to a variety of AD pathologies. The perceived significance of these mitochondrial changes continues to grow, and many currently believe AD mitochondrial dysfunction represents a reasonable therapeutic target. Debate continues over the origin of AD mitochondrial changes. Some argue amyloid-β (Aβ) induces AD mitochondrial dysfunction, a view that does not challenge the amyloid cascade hypothesis and that may in fact help explain that hypothesis. Alternatively, data indicate mitochondrial dysfunction exists independent of Aβ, potentially lies upstream of Aβ deposition, and suggest a primary mitochondrial cascade hypothesis that assumes mitochondrial pathology hierarchically supersedes Aβ pathology. Mitochondria, therefore, appear at least to mediate or possibly even initiate pathologic molecular cascades in AD. This review considers studies and data that inform this area of AD research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondria, too, are damaged by oxidative and nitrosative stress in AD as noted [34].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The presence of Aβ oligomers in mitochondrial membranes is consistent with Aβ-induced mitochondrial dysfunction occurring early in the disease progression timeline [34,53].”
From Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease (2020) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mitochondrial dysfunction plays a fundamental role in AD pathogenesis2 and represents an early event2.”
From Altered mitochondrial dynamics and function in APOE4-expressing astrocytes (2020) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Oxidative stress from mitochondrial dysfunction and reactive oxygen species (ROS) accumulation further heightens neuronal vulnerability [6].”
From What Are the Key Biological Pathways Through Which Lifestyle Factors Influence Neurodegeneration? (2025) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Davis, R. E., Miller, S., Herrnstadt, C., Ghosh, S. S., Fahy, E., Shinobu, L. A., Galasko, D., Thal, L. J., Beal, M. F., Howell, N., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.9.4526 · Cited by 341
RetractedThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Alzheimer's disease: the amyloid cascade hypothesis
Hardy, J. A., & Higgins, G. A. (1992) · Science · doi:10.1126/science.1566067 · Cited by 7,484 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundSperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155 · cited 1×
“plaques may arguably have AD; a current construct refers to this state as “preclinical AD” [144].”
BackgroundHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Premature ageing in mice expressing defective mitochondrial DNA polymerase
Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., Bruder, C. E., Bohlooly-Y, M., Gidlöf, S., Oldfors, A., Wibom, R., et al. (2004) · Nature · doi:10.1038/nature02517 · Cited by 2,734 · cited 1×
“Due to the presence of the mutated mtPOLG transgene, these mice acquire excess somatic mtDNA mutations and mitochondrial dysfunction [65, 66].”
BackgroundAmyloid deposition as the central event in the aetiology of Alzheimer’s disease
Hardy, J., & Allsop, D. (1991) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(91)90609-v · Cited by 2,538 · cited 1×
“Based on assumptions made by the amyloid cascade hypothesis, first proposed in the early 1990 s [22, 23], the latter possibility seemed more likely.”
BackgroundBloom (2014) · doi:10.1001/jamaneurol.2013.5847 · Cited by 2,194 · cited 1×
“In response to this, some now speculate A itself is insufficient to cause the disease, but instead initiates AD by triggering a critical change in tau biology [114, 119, 120].”
Background
Research works printed but not linked: 1
- Parker WD (1990) Sporadic neurologic disease and the electron transport chain: A hyothesis In Proceedings of the 1989 Scientific Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease, Pascuzzi RM, ed. Indiana University Printing Services, Bloomington, Indiana.
Cited by
Mitochondria dysfunction in the pathogenesis of Alzheimer’s disease: Recent advances.
Wang, W., Zhao, F., Ma, X., Perry, G., & Zhu, X. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00376-6 · Cited by 1,274
Ferroptosis and Cancer: Mitochondria Meet the “Iron Maiden” Cell Death
Battaglia, A. M., Chirillo, R., Aversa, I., Sacco, A., Costanzo, F., & Biamonte, F. (2020) · Cells · doi:10.3390/cells9061505 · Cited by 561
Gut microbiota and dysbiosis in Alzheimer's disease: Implications for pathogenesis and treatment
Liu, S., Gao, J., Zhu, M., Liu, K., & Zhang, H.-L. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02073-3 · Cited by 516
“Extensive research argues mitochondrial dysfunction [13], insulin resistance (IR) [14], and cerebral hypoperfusion [15] may mediate, drive, or possibly even initiate pathologic molecular cascades in AD and finally promote Aβ accumulation, tau hyperphosphorylation, synaptic degeneration, and neuronal dysfunction.”
BackgroundMitochondrial Oxidative Stress—A Causative Factor and Therapeutic Target in Many Diseases
Kowalczyk, P., Sulejczak, D., Kleczkowska, P., Bukowska-Ośko, I., Kucia, M., Popiel, M., Wietrak, E., Kramkowski, K., Wrzosek, K., & Kaczyńska, K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413384 · Cited by 495
“Oxidative damage and neuroinflammation have been shown to correlate with Alzheimer’s disease progression [41,44].”
BackgroundAmyloid Beta and Phosphorylated Tau-Induced Defective Autophagy and Mitophagy in Alzheimer’s Disease
Reddy, P. H., & Oliver, D. M. (2019) · Cells · doi:10.3390/cells8050488 · Cited by 496
“, Huntington’s disease [39], amyotrophic lateral sclerosis [40], Parkinson’s disease [41], Friedreich ataxia [42], Alzheimer’s disease [43]), and chronic liver diseases (e.”
BackgroundAlzheimer’s disease and its treatment by different approaches: A review
Srivastava, S., Ahmad, R., & Khare, S. K. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113320 · Cited by 467
The role of mitochondrial dysfunction in Alzheimer's disease pathogenesis
Ashleigh, T., Swerdlow, R. H., & Beal, M. F. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12683 · Cited by 468
Self-citationYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Targeting Nrf2 to Suppress Ferroptosis and Mitochondrial Dysfunction in Neurodegeneration
Abdalkader, M., Lampinen, R., Kanninen, K. M., Malm, T. M., & Liddell, J. R. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00466 · Cited by 423
“Moreover, impaired mitochondrial function is Frontiers in Neuroscience | www.frontiersin.org 3 July 2018 | Volume 12 | Article 466 common to many neurodegenerative diseases (Carri et al., 2017; Liddell and White, 2017; Liot et al., 2017; Swerdlow, 2017).”
BackgroundMitochondrial dysfunction in neurodegenerative disorders
Klemmensen, M. M., Borrowman, S. H., Pearce, C., Pyles, B., & Chandra, B. (2024) · Neurotherapeutics · doi:10.1016/j.neurot.2023.10.002 · Cited by 396
“Impor-tantly, A β has also been found to disrupt intracellular calcium homeostasis, leading to increased cell membrane excitability and neuronal dysfunction [138,140].”
BackgroundInfluentialTraumatic Brain Injury and Alzheimer's Disease: The Cerebrovascular Link
Ramos-Cejudo, J., Wisniewski, T., Marmar, C., Zetterberg, H., Blennow, K., de Leon, M. J., & Fossati, S. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.01.021 · Cited by 385
Nativio, R., Lan, Y., Donahue, G., Sidoli, S., Berson, A., Srinivasan, A. R., Shcherbakova, O., Amlie-Wolf, A., Nie, J., Cui, X., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0696-0 · Cited by 380
Monzio Compagnoni, G., Di Fonzo, A., Corti, S., Comi, G. P., Bresolin, N., & Masliah, E. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-01926-1 · Cited by 378
“On the other hand, according to the mitochondrial cascade hypothesis, mitochondrial dysfunction would represent the initial trigger of most AD cases and the other pathological features should be considered as a secondary effect [10, 11].”
BackgroundMechanisms of sex differences in Alzheimer’s disease
Lopez-Lee, C., Torres, E. R. S., Carling, G., & Gan, L. (2024) · Neuron · doi:10.1016/j.neuron.2024.01.024 · Cited by 376
Synaptic basis of Alzheimer’s disease: Focus on synaptic amyloid beta, P-tau and mitochondria
John, A., & Reddy, P. H. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101208 · Cited by 359
“This then causes the mitochondria, one of the cell’s calcium regulators, to take in the calcium as well (Swerdlow, 2018).”
BackgroundAlzheimer’s Disease Pharmacotherapy in Relation to Cholinergic System Involvement
Stanciu, G. D., Luca, A., Rusu, R. N., Bild, V., Beschea Chiriac, S. I., Solcan, C., Bild, W., & Ababei, D. C. (2019) · Biomolecules · doi:10.3390/biom10010040 · Cited by 297
Oxidative stress and mitochondrial impairment: Key drivers in neurodegenerative disorders
Wen, P., Sun, Z., Gou, F., Wang, J., Fan, Q., Zhao, D., & Yang, L. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102667 · Cited by 253
Mitophagy in Alzheimer’s disease: Molecular defects and therapeutic approaches
Mary, A., Eysert, F., Checler, F., & Chami, M. (2023) · Molecular Psychiatry · doi:10.1038/s41380-022-01631-6 · Cited by 244
Jamwal, S., Blackburn, J. K., & Elsworth, J. D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107705 · Cited by 236
“This is supported by evidence of Aβ accumulation inside brain mitochondria of patients with AD (Pavlov, Petersen, Glaser, & Ankarcrona, 2009; Swerdlow, 2018).”
BackgroundMitochondrial Dysfunction as a Driver of Cognitive Impairment in Alzheimer’s Disease
Sharma, C., Kim, S., Nam, Y., Jung, U. J., & Kim, S. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094850 · Cited by 234
“Thus, accrued mitochondrial damage due to insults such as oxidative stress and accumulation of Aβ oligomers may act synergistically to further damage mitochondria and drive AD pathology [27].”
BackgroundDewanjee, S., Chakraborty, P., Bhattacharya, H., Chacko, L., Singh, B., Chaudhary, A., Javvaji, K., Pradhan, S. R., Vallamkondu, J., Dey, A., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.09.032 · Cited by 229
Doblado, L., Lueck, C., Rey, C., Samhan-Arias, A. K., Prieto, I., Stacchiotti, A., & Monsalve, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22083903 · Cited by 228
Dysfunctional Mitochondria and Mitophagy as Drivers of Alzheimer’s Disease Pathogenesis
Chakravorty, A., Jetto, C. T., & Manjithaya, R. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00311 · Cited by 219
“Therefore, the focus has now shifted to mitochondria as one of the central players in the pathogenesis of AD (Cadonic et al., 2016; Cai and Tammineni, 2017; Cardoso et al., 2017; Guo et al., 2017; Martin-Maestro et al., 2017; Swerdlow, 2018).”
BackgroundOxidative Stress and Dementia in Alzheimer’s Patients: Effects of Synbiotic Supplementation
Ton, A. M. M., Campagnaro, B. P., Alves, G. A., Aires, R., Côco, L. Z., Arpini, C. M., Guerra e Oliveira, T., Campos-Toimil, M., Meyrelles, S. S., Pereira, T. M. C., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/2638703 · Cited by 217
Role of Platelet Mitochondria: Life in a Nucleus-Free Zone
Melchinger, H., Jain, K., Tyagi, T., & Hwa, J. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2019.00153 · Cited by 208
“Because mitochondria play such an integral role in platelet metabolism, activation, and apoptosis, it is no surprise that mitochondrial dysfunction contribute to dysfunctional platelet activity and apoptosis in several diseases, most notably Alzheimer’s and Parkinson’s (120), cardiovascular disease (CVD) (121), diabet…”
InfluentialMitochondrial dynamics and transport in Alzheimer's disease
Flannery, P. J., & Trushina, E. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.009 · Cited by 202
Mesenchymal stem cell-derived exosome: a promising alternative in the therapy of Alzheimer’s disease
Guo, M., Yin, Z., Chen, F., & Lei, P. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00670-x · Cited by 200
“However, accumulating evidence demonstrate that amyloid cascade hypothesis fail to explain the pathophysiological mechanism of AD completely, and tau hypothesis, mitochondrial cascade hypothesis, and neuroinflammation hypothesis are proposed successively [50, 51].”
BackgroundHan, Y., Gao, C., Wang, H., Sun, J., Liang, M., Feng, Y., Liu, Q., Fu, S., Cui, L., Gao, C., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.08.017 · Cited by 197
Bustamante-Barrientos, F. A., Luque-Campos, N., Araya, M. J., Lara-Barba, E., de Solminihac, J., Pradenas, C., Molina, L., Herrera-Luna, Y., Utreras-Mendoza, Y., Elizondo-Vega, R., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04493-w · Cited by 184
“attention, memory, reasoning, language and/or visual-spatial abnormalities—are well-recognized as a multi-etiology symptom, a growing number of studies highlights their association with mitochondrial dysfunction [25, 35].”
BackgroundAstrocytes in Alzheimer's disease: pathological significance and molecular pathways
Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., & Arranz, A. M. (2021) · Cells · doi:10.3390/cells10030540 · Cited by 176
Astrocytes in Alzheimer´s Disease: Pathological Significance and Molecular Pathways
Preman, P., Alfonso-Triguero, M., Alberdi, E., Verkhratsky, A., & Arranz, A. M. (2021) · doi:10.20944/preprints202102.0230.v1 · Cited by 176
Barone, E., Di Domenico, F., Perluigi, M., & Butterfield, D. A. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.09.006 · Cited by 172
The Toxicity and Polymorphism of β-Amyloid Oligomers
Huang, Y.-R., & Liu, R.-T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124477 · Cited by 159
“Moreover, the destruction of intracellular Ca2+ homeostasis causes mitochondrial Ca2+ overload and mitochondrial dysfunction [78,79].”
BackgroundApolipoprotein E and Alzheimer's disease
Troutwine, B. R., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. M. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 156
Fabrício, D. D. M., Chagas, M. H. N., & Diniz, B. S. (2020) · Translational research · doi:10.1016/j.trsl.2020.01.002 · Cited by 169
Air Pollution and Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Fu, P., & Yung, K. K. L. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200483 · Cited by 146
“…brain injury, some toxicological studies revealed that air pollutants (such as PM, O 3 , NO 2 , SO 2 , and CO) might cause brain injury and neurotoxicity [22–25] through regulation roles related to mitochondrial damage, oxidative stress, and inflammation, which are involved in AD pathology [26, 27].”
Mechanisms of protein toxicity in neurodegenerative diseases
Chung, C. G., Lee, H., & Lee, S. B. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2854-4 · Cited by 142
The interaction between ageing and Alzheimer's disease: insights from the hallmarks of ageing
Liu, Y., Tan, Y., Zhang, Z., Yi, M., Zhu, L., & Peng, W. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00397-x · Cited by 174
“Mitochondrial dysfunction may be secondary to abnormal deposition of neuropathological markers (APP, Aβ and tau), or a primary mitochondrial cascade may directly disturb vital brain functions [119].”
BackgroundYang, P., Sheng, D., Guo, Q., Wang, P., Xu, S., Qian, K., Li, Y., Cheng, Y., Wang, L., Lu, W., et al. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119844 · Cited by 137
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
Berlanga-Acosta, J., Guillén-Nieto, G., Rodríguez-Rodríguez, N., Bringas-Vega, M. L., García-del-Barco-Herrera, D., Berlanga-Saez, J. O., García-Ojalvo, A., Valdés-Sosa, M. J., & Valdés-Sosa, P. A. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.560375 · Cited by 136
“Aβ progressively accumulates within mitochondria and impairs a variety of its functions (226, 259).”
BackgroundFields, M., Marcuzzi, A., Gonelli, A., Celeghini, C., Maximova, N., & Rimondi, E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043739 · Cited by 156
“Mitochondrial defects and oxidative stress may result from age, sedentary lifestyle, poor exercise and a high-calorie diet [43,45].”
BackgroundResultVillavicencio-Tejo, F., & Quintanilla, R. A. (2021) · Antioxidants · doi:10.3390/antiox10071069 · Cited by 152
“AD brain develops two distinguished pathological characteristics: the senile plaques formed by extracellular deposits of the β-amyloid peptide Aβ (1–40), Aβ (1–42) and the neurofibrillary tangles (NFTs) made of intraneuronal aggregations of hyperphosphorylated tau protein [235].”
BackgroundMitochondria‐targeted nanoparticles in treatment of neurodegenerative diseases
Zhang, Y., Yang, H. N., Wei, D., Zhang, X., Wang, J., Wu, X., & Chang, J. K. (2021) · Exploration · doi:10.1002/exp.20210115 · Cited by 146
Rehman, M. U., Sehar, N., Dar, N. J., Khan, A., Arafah, A., Rashid, S., Rashid, S. M., & Ganaie, M. A. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104961 · Cited by 130
Mitochondrial complex I as a therapeutic target for Alzheimer's disease
Trushina, E. V., Trushin, S., & Hasan, M. F. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.11.003 · Cited by 141
Altered mitochondrial dynamics and function in APOE4-expressing astrocytes
Schmukler, E., Solomon, S., Simonovitch, S., Goldshmit, Y., Wolfson, E., Michaelson, D. M., & Pinkas-Kramarski, R. (2020) · Cell Death & Disease · doi:10.1038/s41419-020-02776-4 · Cited by 125
Ryu, W.-I., Bormann, M. K., Shen, M., Kim, D., Forester, B., Park, Y., So, J., Seo, H., Sonntag, K.-C., & Cohen, B. M. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01068-3 · Cited by 125
Astrocyte-Neuron Metabolic Crosstalk in Neurodegeneration: A Mitochondrial Perspective
Mulica, P., Grünewald, A., & Pereira, S. L. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.668517 · Cited by 123
“Since data on the role of astrocytic mitochondria in PD is still sparse [reviewed in (76, 95)] further experiments will be required to assess how astrocyte metabolism as well as astrocyte-neuron coupling may contribute to the development of the movement disorder.”
BackgroundRelationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer’s Disease
Wong, K. Y., Roy, J., Fung, M. L., Heng, B. C., Zhang, C., & Lim, L. W. (2020) · Aging and disease · doi:10.14336/ad.2019.1125 · Cited by 119
“The primary cascade is similar to the original hypothesis that mitochondrial dysfunction induces pathological hallmarks such as Aβ and P-tau [13, 17], whereas the secondary cascade posits that mitochondrial dysfunction is an intermediate step majorly initiated by Aβ deposition [17].”
BackgroundInfluentialNeurobiological Highlights of Cognitive Impairment in Psychiatric Disorders
Morozova, A. Y., Zorkina, Y., Abramova, O. V., Pavlova, O., Ka, P., Soloveva, K., Volkova, M., Alekseeva, P. A., Andryshchenko, A., Kostyuk, G. P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031217 · Cited by 143
“Mitochondrial dysfunction leads to disruption of the following processes: changes in neurotransmitter systems, the generation of reactive oxygen and nitrogen forms, cell stress response, Ca2+ signaling, disturbances in glucose and lipid metabolism, changes in amyloidbeta (Aβ) metabolism, protein aggregation, disruptio…”
BackgroundInfluentialAMPK: A bridge between diabetes mellitus and Alzheimer's disease
Chen, M., Huang, N., Liu, J., Huang, J., Shi, J., & Jin, F. J. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.113043 · Cited by 126
Strosznajder, A. K., Wójtowicz, S., Jeżyna, M. J., Sun, G. Y., & Strosznajder, J. B. (2020) · NeuroMolecular Medicine · doi:10.1007/s12017-020-08629-9 · Cited by 137
“2012; Swerdlow 2018).”
Oudbier, S. J., Goh, J., Looijaard, S. M. L. M., Reijnierse, E. M., Meskers, C. G. M., & Maier, A. B. (2022) · The Journals of Gerontology Series A · doi:10.1093/gerona/glac121 · Cited by 138
“The “mitochondrial cascade hypothesis” suggests that ageassociated mitochondrial decline occurs at a certain threshold and is concomitant with synaptic loss, Aβ production, tau phosphorylation, and plaque deposition in the brain (102).”
BackgroundThe Multifaceted Regulation of Mitochondria in Ferroptosis
Wu, H., Wang, F., Ta, N., Zhang, T., & Gao, W. (2021) · Life · doi:10.3390/life11030222 · Cited by 122
On the central role of mitochondria dysfunction and oxidative stress in Alzheimer’s disease
Tobore, T. O. (2019) · Neurological Sciences · doi:10.1007/s10072-019-03863-x · Cited by 120
Peng, Y., Gao, P., Shi, L., Chen, L., Liu, J., & Long, J. (2020) · Antioxidants & Redox Signaling · doi:10.1089/ars.2019.7763 · Cited by 110
“These abilities suggest that mitochondria are uniquely significant in age-related diseases, especially in AD progression (378).”
BackgroundMichalska, P., & Leon, R. M. (2020) · Antioxidants · doi:10.3390/antiox9080740 · Cited by 119
Navarro, J. F., Croteau, D. L., Jurek, A., Andrusivova, Z., Yang, B., Wang, Y., Ogedegbe, B., Riaz, T., Støen, M., Desler, C., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101556 · Cited by 106
“…Del-Aguila et al. (2019). ll OPEN ACCESS iScience 23, 101556, October 23, 2020 13 iScience Article ll OPEN ACCESS BOK, a Spatially Expressed Gene in Hippocampal CA3 Regions, Shows Loss of Expression in Mouse and Human AD Brains Dysfunctional mitochondria contribute to AD pathology (Swerdlow, 2018).”
BackgroundFišar, Z. (2022) · Biomolecules · doi:10.3390/biom12111676 · Cited by 120
“Impaired neuroplasticity [235] and mitochondrial dysfunction [211] could be a common upstream etiology of AD an are responsible for the effects of multiple risk factors and biomarkers, including Aβ elevation and tau hyperphosphorylation.”
BackgroundWang, Z., Wang, C., Yuan, B., Liu, L., Zhang, H., Zhu, M., Chai, H., Peng, J., Huang, Y. H., Zhou, S., et al. (2025) · Microbiome · doi:10.1186/s40168-024-02001-w · Cited by 132
The heat shock response and small molecule regulators
Kurop, M. K., Huyen, C. M., Kelly, J. H., & Blagg, B. S. J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113846 · Cited by 112
Dhapola, R., Sarma, P., Medhi, B., Prakash, A., & HariKrishnaReddy, D. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02612-6 · Cited by 123
“Further, Aβ was added to the cells deprived of mitochondrial DNA (mtDNA), NT2 p0 cells, but as these cells did not contain mtDNA, they were deprived of any damage caused by Aβ suggesting the involvement of mitochondria in Aβ toxicity leading to cell death [55].”
BackgroundLi, H., Slone, J. D., Fei, L., & Huang, T. (2019) · Cells · doi:10.3390/cells8060608 · Cited by 115
“There is even evidence that mitochondrial defects may actually help induce the formation of Aβ aggregates [21], potentially placing it upstream of the latter in the overall mechanism of AD pathology.”
BackgroundIn Vivo Mitochondrial and Glycolytic Impairments in Patients with Alzheimer Disease
Terada, T., Obi, T., Bunai, T., Matsudaira, T., Yoshikawa, E., Ando, I., Futatsubashi, M., Tsukada, H., & Ouchi, Y. (2020) · Neurology · doi:10.1212/wnl.0000000000009249 · Cited by 103
“In contrast, an in vitro and animal-based study reported that dysfunctional mitochondria might be one mechanism underlying the etiopathology of AD according to the mitochondrial cascade hypothesis, regardless of the presence of Aβ.(8) These experimental reports focused chiefly on the beginning stage to assess pathophy…”
BackgroundCa2+ handling at the mitochondria-ER contact sites in neurodegeneration
Lim, D., Dematteis, G., Tapella, L., Genazzani, A. A., Calí, T., Brini, M., & Verkhratsky, A. (2021) · Cell Calcium · doi:10.1016/j.ceca.2021.102453 · Cited by 116
Mitochondria Dysfunction and Neuroinflammation in Neurodegeneration: Who Comes First?
Peggion, C., Calí, T., & Brini, M. (2024) · Antioxidants · doi:10.3390/antiox13020240 · Cited by 124
“Taking into consideration all the abovementioned mitochondrial dysfunctions in AD, in addition to the most popular amyloid hypothesis for AD pathogenesis, some authors have proposed the mitochondrial hypothesis [19,60,61].”
BackgroundCurrent progress of mitochondrial transplantation that promotes neuronal regeneration
Chang, C.-Y., Liang, M.-Z., & Chen, L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0158-8 · Cited by 110
Venkataraman, A. V., Mansur, A., Rizzo, G., Bishop, C., Lewis, Y., Kocagoncu, E., Lingford-Hughes, A., Huiban, M., Passchier, J., Rowe, J. B., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1051 · Cited by 101
“Oxidative and endoplasmic reticulum (ER) stress, prominent metabolic features (7, 8) of early AD (9, 10), are associated with reduced cerebral blood flow (CBF) (11) and with up-regulation of the sigma 1 receptor (S1R) in the ER (12, 13).”
BackgroundMitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis
Weidling, I. W., & Swerdlow, R. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113321 · Cited by 101
“An AD mitochondrial cascade hypothesis A mitochondrial cascade hypothesis argues AD neuropathology arises secondary to mitochondrial dysfunction (Swerdlow, 2018; Swerdlow et al., 2010, 2014; Swerdlow and Khan, 2004; Swerdlow and Khan, 2009).”
BackgroundSelf-citationValenti, D., Vacca, R. A., Moro, L., & Atlante, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158312 · Cited by 104
Synaptic plasticity in Alzheimer’s disease and healthy aging
Cuestas Torres, D. M., & Cardenas, F. P. (2020) · Reviews in the Neurosciences · doi:10.1515/revneuro-2019-0058 · Cited by 98
Axonal Degeneration in AD: The Contribution of Aβ and Tau
Salvadores, N., Gerónimo-Olvera, C., & Court, F. A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.581767 · Cited by 96
“…| www.frontiersin.org 8 October 2020 | Volume 12 | Article 581767 the process of axonal degeneration, including mitochondrial dysfunction (Swerdlow, 2018; Albensi, 2019), oxidative stress (Butterfield and Boyd-Kimball, 2018; Cheignon et al., 2018) and calcium dyshomeostasis (Mata, 2018;…”
BackgroundMira, R. G., & Cerpa, W. F. (2020) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-020-00924-0 · Cited by 103
“Several reports have indicated the presence of Aβ into the mitochondria, bound to CypD, probably partially explaining the OXPHOS deficiency in AD patients and models (Swerdlow 2018).”
BackgroundIs Alzheimer’s disease an inflammasomopathy?
Pereira, C. F., Santos, A. E., Moreira, P. I., Pereira, A. C., Sousa, F. J., Cardoso, S. M., & Cruz, M. T. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100966 · Cited by 94
Mitochondrial Behavior in Axon Degeneration and Regeneration
Wang, B., Huang, M., Shang, D., Yan, X., Zhao, B., & Zhang, X. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.650038 · Cited by 115
“Axon degeneration in AD involves a complicated mechanism, including glucose metabolism defects, mitochondrial dysfunction, aberrant calcium homeostasis, oxidative stress, and imbalances in energy homeostasis (Cieri et al., 2018; Mata, 2018; Swerdlow, 2018; Albensi, 2019).”
BackgroundSalech, F., Ponce, D. P., Paula-Lima, A. C., SanMartín, C. D., & Behrens, M. I. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00255 · Cited by 99
“Mitochondria and AD More recently different lines of evidence support a role for mitochondrial dysfunction as a central event in the pathogenesis of AD, where several mitochondrial parameters such as oxygen consumption, ATP production, ROS generation, Ca2+ signals, mitochondrial dynamic and mitophagy, are altered (Mar…”
BackgroundInfluentialQian, K., Bao, X., Li, Y., Wang, P., Guo, Q., Yang, P., Xu, S., Yu, F., Meng, R., Cheng, Y., et al. (2022) · ACS Nano · doi:10.1021/acsnano.2c05795 · Cited by 84
Mitochondrial Oxidative and Nitrosative Stress and Alzheimer Disease
Butterfield, D. A., & Boyd-Kimball, D. (2020) · Antioxidants · doi:10.3390/antiox9090818 · Cited by 85
“Consequently, evidence consistent with the tenants of the Primary Mitochondrial Cascade hypothesis were obtained, suggesting, similar to that posited by Swerdlow, both cascades are in play in AD and MCI that coalesce in the brain as decreased glucose metabolism evidenced by altered glycolysis and mitochondria.”
BackgroundInfluentialde Dios, C., Abadin, X., Roca-Agujetas, V., Jimenez-Martinez, M., Morales, A., Trullas, R., Mari, M., & Colell, A. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00343-3 · Cited by 85
“Mitochondrial impairment is recognized as a common early event in AD that precedes amyloid plaque deposition and cognitive deficits [17].”
BackgroundGray, N. E., Zweig, J. A., Caruso, M., Zhu, J. Y., Wright, K. M., Quinn, J. F., & Soumyanath, A. (2018) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.09.002 · Cited by 85
“…in the brain are thought to precede, or even induce, cognitive decline in AD (Brown and Borutaite, 2002; Manczak et al., 2004; Yao et al., 2009; Swerdlow, 2018) and increased oxidative stress is similarly considered to be an early event in the brains of AD patients (Serrano and Klann, 2004;…”
Li, J., Wei, Y., Zhang, C., Bi, R., Qiu, Y., Li, Y., & Hu, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020621 · Cited by 85
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.01.008 · Cited by 85
“Considerations such as these support the argument that mitochondria independently contribute to AD risk and progression, and support speculation of a pathological mitochondrial cascade (Swerdlow, 2018; Swerdlow et al., 2010, 2014; Swerdlow & Khan, 2004, 2009; Swerdlow et al., 2017).”
BackgroundSelf-citationTauopathies: Deciphering Disease Mechanisms to Develop Effective Therapies
Silva, M. C., & Haggarty, S. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21238948 · Cited by 85
Mitochondrial dysfunction and neurological disorders: A narrative review and treatment overview
Alshial, E. E., Abdulghaney, M. I., Wadan, A. S., Abdellatif, M. A., Ramadan, N. E., Suleiman, A. M., Waheed, N., Abdellatif, M., & Mohammed, H. S. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122257 · Cited by 98
Nowak-Jary, J., & Machnicka, B. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252212013 · Cited by 74
Mitochondrial Dysfunction in Neurodegenerative Diseases
Yang, H. (2025) · Cells · doi:10.3390/cells14040276 · Cited by 103
Nanomaterials toward the treatment of Alzheimer’s disease: Recent advances and future trends
Zeng, H., Qi, Y., Zhang, Z., Liu, C., Peng, W., & Zhang, Y. (2021) · Chinese Chemical Letters · doi:10.1016/j.cclet.2021.01.014 · Cited by 83
Galea, E., Weinstock, L. D., Larramona-Arcas, R., Pybus, A. F., Giménez-Llort, L., Escartin, C., & Wood, L. B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105655 · Cited by 83
Fracassi, A., Marcatti, M., Zolochevska, O., Tabor, N., Woltjer, R., Moreno, S., & Taglialatela, G. (2021) · The Journal of Neuroscience · doi:10.1523/jneurosci.0295-20.2020 · Cited by 81
“Particularly, given the well established role of mitochondrial dysfunction as one of the central cytopathologies of AD (Reddy, 2014; Sweeney and Song, 2016; Swerdlow, 2018; Perez Ortiz and Swerdlow, 2019), we analyzed the expression of the mitochondrial O2 –.”
BackgroundSingulani, M. P., Pereira, C. P. M., Ferreira, A. F. F., Garcia, P. C., Ferrari, G. D., Alberici, L. C., & Britto, L. R. (2020) · Experimental Gerontology · doi:10.1016/j.exger.2020.110882 · Cited by 80
Tao, Y., Han, Y., Yu, L., Wang, Q., Leng, S. X., & Zhang, H. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00233 · Cited by 79
“In our study, ATP5C1 and RPS27A were regarded as major pathogenic genes of MCI, which is consistent with the conclusions that mitochondrial dysfunction and oxidative stress are closely associated with progression of cognitive impairment (40).”
ResultThe Alzheimer’s Disease Mitochondrial Cascade Hypothesis: A Current Overview
Swerdlow, R. H. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-221286 · Cited by 93
“Thissce-nario is consistent with the possibility of a secondary mitochondrial cascade [14].”
Self-citationCan exercise training teach us how to treat Alzheimer's disease?
Huuha, A. M., Norevik, C. S., Moreira, J. B. N., Kobro-Flatmoen, A., Scrimgeour, N., Kivipelto, M., Van Praag, H., Ziaei, M., Sando, S. B., Wisløff, U., et al. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101559 · Cited by 79
“Other pathological events in early, preclinical AD include neuroinflammation (Heppner et al., 2015), impaired glucose metabolism (An et al., 2018), and loss of mitochondrial function and dynamics (Swerdlow, 2018).”
BackgroundThe Links between Cardiovascular Diseases and Alzheimer's Disease
Leszek, J., Вячеславовна, М. Е., Belousov, D. M., Koutsouraki, E., Szczechowiak, K., Kobusiak−Prokopowicz, M., Mysiak, A., Diniz, B. S., Somasundaram, S. G., Kirkland, C. E., et al. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200729093724 · Cited by 115
“While there is no scientific consensus on the root cause of SAD, mitochondrial disorders play a crucial role in both amyloid theory and mitochondrial one [196].”
BackgroundTerada, T., Therriault, J., Kang, M. S., Savard, M., Pascoal, T. A., Lussier, F. Z., Tissot, C., Wang, Y.-T., Benedet, A. L., Matsudaira, T., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00448-1 · Cited by 84
Neurotoxic β-amyloid oligomers cause mitochondrial dysfunction—the trigger for PANoptosis in neurons
Meng, X., Song, Q., Liu, Z., Liu, X., Wang, Y., & Liu, J. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1400544 · Cited by 88
“Mitochondrial dysfunction is a core feature of neurodegenerative diseases (Swerdlow, 2018; Cheng et al., 2022).”
BackgroundIdentification of Conserved Proteomic Networks in Neurodegenerative Dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Dai, J., Lah, J. J., Johnson, E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107807 · Cited by 78
Identification of conserved proteomic networks in neurodegenerative dementia
Swarup, V., Chang, T. S., Duong, D. M., Dammer, E. B., Lah, J. J., Johnson, E. E. C. B., Seyfried, N. T., Levey, A. I., & Geschwind, D. H. (2019) · doi:10.1101/825802 · Cited by 78
Carelli, S., Rey, F., Ottolenghi, S., Zuccotti, G., & Samaja, M. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.322430 · Cited by 82
“…impaired activity of pyruvate dehydrogenase, ketoglutarate dehydrogenase and cytochrome oxidase, impaired oxygen consumption and altered morphology, implies that mitochondrial dysfunction is the initial trigger for AD (Swerdlow et al., 2010; Swerdlow, 2018; Monzio Compagnoni et al., 2020).”
Cytochrome b5 reductases: Redox regulators of cell homeostasis
Hall, R., Yuan, S. S., Wood, K. C., Katona, M., & Straub, A. C. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.102654 · Cited by 84
“Mitochondrial dysfunction is an established feature of Alzheimer’s disease (101, 102) and in the frequently utilized 5xFAD mouse model, a model that has a total of five Alzheimer’s disease–linked mutations: the Swedish (K670N/M671L), Florida (I716V), and London (V717I) mutations in APP and the M146L and L286V mutation…”
Background
Metadata
- Authors
- Swerdlow, R. H.
- Affiliations
- University of Kansas (US)
- Corresponding author
- Swerdlow, Russell H.
- ORCID
- Swerdlow, Russell H.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2017-10-07
- Volume
- 62
- Issue
- 3
- Pages
- 1403-1416
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC5869994
- OpenAlex
- W2764071986
- Cited by
- 850
- References
- 154
- Citations by year
- 2026: 126 · 2025: 106 · 2024: 97 · 2023: 110 · 2022: 122 · 2021: 114 · 2020: 106 · 2019: 49 · 2018: 18 · 2017: 1
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- National Institute on Aging (P30AG035982)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, mitochondrial dysfunction
- MeSH terms
- Alzheimer Disease, Animals, Humans, Mitochondria
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.